<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Clinuvel Pharmaceuticals Ltd — News on 6ix</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd</link>
<description>Latest news and press releases for Clinuvel Pharmaceuticals Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 05:47:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/clinuvel-pharmaceuticals-ltd" rel="self" type="application/rss+xml" />
<item>
<title>CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-receives-final-ema-scientific-advice-for-pivotal-phase-iii-vitiligo-study</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-receives-final-ema-scientific-advice-for-pivotal-phase-iii-vitiligo-study</guid>
<pubDate>Fri, 24 Apr 2026 05:47:00 GMT</pubDate>
<description>“Totality of evidence” approach to evaluate SCENESSE®EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its “totality of evidence” approachcentral photographic review and validated disease assessment tools agreedCUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapyCUV107 study (n=300) to commence in 2H 2026 MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the Euro</description>
</item>
<item>
<title>CLINUVEL's global programs showcased at AAD</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvels-global-programs-showcased-at-aad</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvels-global-programs-showcased-at-aad</guid>
<pubDate>Fri, 27 Mar 2026 01:56:04 GMT</pubDate>
<description>CLINUVEL's global programs showcased at AAD</description>
</item>
<item>
<title>Chair Letter to Shareholders</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/chair-letter-to-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/chair-letter-to-shareholders</guid>
<pubDate>Fri, 20 Mar 2026 01:51:04 GMT</pubDate>
<description>Chair Letter to Shareholders</description>
</item>
<item>
<title>Half Year Results Presentation</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/half-year-results-presentation-74</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/half-year-results-presentation-74</guid>
<pubDate>Thu, 26 Feb 2026 04:18:17 GMT</pubDate>
<description>Half Year Results Presentation</description>
</item>
<item>
<title>CLINUVEL Record Revenues, Advances Strategic Expansion</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-record-revenues-advances-strategic-expansion</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-record-revenues-advances-strategic-expansion</guid>
<pubDate>Thu, 26 Feb 2026 04:16:06 GMT</pubDate>
<description>CLINUVEL Record Revenues, Advances Strategic Expansion</description>
</item>
<item>
<title>Appendix 4D and Half Year Report</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/appendix-4d-and-half-year-report-102</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/appendix-4d-and-half-year-report-102</guid>
<pubDate>Thu, 26 Feb 2026 04:15:12 GMT</pubDate>
<description>Appendix 4D and Half Year Report</description>
</item>
<item>
<title>CLINUVEL - injectable peptide platform in preclinical study</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-injectable-peptide-platform-in-preclinical-study</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-injectable-peptide-platform-in-preclinical-study</guid>
<pubDate>Mon, 12 Jan 2026 03:03:13 GMT</pubDate>
<description>CLINUVEL - injectable peptide platform in preclinical study</description>
</item>
<item>
<title>CLINUVEL expands Singapore RD&I Centre</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-expands-singapore-rdandi-centre</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-expands-singapore-rdandi-centre</guid>
<pubDate>Mon, 08 Dec 2025 02:53:17 GMT</pubDate>
<description>CLINUVEL expands Singapore RD&I Centre</description>
</item>
<item>
<title>CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-expands-singapore-rd-centre-023700781</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-expands-singapore-rd-centre-023700781</guid>
<pubDate>Mon, 08 Dec 2025 02:37:00 GMT</pubDate>
<description>CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of l</description>
</item>
<item>
<title>CLINUVEL advances new formulations in preclinical program</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-advances-new-formulations-in-preclinical-program</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-advances-new-formulations-in-preclinical-program</guid>
<pubDate>Mon, 29 Sep 2025 02:57:07 GMT</pubDate>
<description>CLINUVEL advances new formulations in preclinical program</description>
</item>
<item>
<title>CLINUVEL to advance novel pharmaceutical formulations in preclinical program</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-advance-novel-pharmaceutical-formulations-025600802</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-advance-novel-pharmaceutical-formulations-025600802</guid>
<pubDate>Mon, 29 Sep 2025 02:56:00 GMT</pubDate>
<description>Next generation sustained-release formulations for a variety of peptidesExecutive summary first biocompatible pharmaceutical formulations progress to preclinical modelsnew sustained-release drug delivery platforms for peptides, melanocortinsaim to predict drug release kinetics from new formulationsliquid formulation allows flexible dosing through adjusting injection volumesperseverance during 10 years of in-house research MELBOURNE, Australia, Sept. 28, 2025 (GLOBE NEWSWIRE) -- CLINUVEL today an</description>
</item>
<item>
<title>EMA approves year-round SCENESSE treatment</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/ema-approves-year-round-scenesse-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/ema-approves-year-round-scenesse-treatment</guid>
<pubDate>Tue, 23 Sep 2025 02:53:23 GMT</pubDate>
<description>EMA approves year-round SCENESSE treatment</description>
</item>
<item>
<title>SCENESSE efficacy in vitiligo - new cases presented to EADV</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/scenesse-efficacy-in-vitiligo-new-cases-presented-to-eadv</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/scenesse-efficacy-in-vitiligo-new-cases-presented-to-eadv</guid>
<pubDate>Fri, 19 Sep 2025 02:46:12 GMT</pubDate>
<description>SCENESSE efficacy in vitiligo - new cases presented to EADV</description>
</item>
<item>
<title>Investor Presentation</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/investor-presentation-481</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/investor-presentation-481</guid>
<pubDate>Thu, 28 Aug 2025 03:57:48 GMT</pubDate>
<description>Investor Presentation</description>
</item>
<item>
<title>CLINUVEL delivers ninth consecutive revenues growth & profit</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-delivers-ninth-consecutive-revenues-growth-and-profit</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-delivers-ninth-consecutive-revenues-growth-and-profit</guid>
<pubDate>Thu, 28 Aug 2025 03:56:57 GMT</pubDate>
<description>CLINUVEL delivers ninth consecutive revenues growth & profit</description>
</item>
<item>
<title>Appendix 4E and Annual Report to Shareholders 2025</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/appendix-4e-and-annual-report-to-shareholders-2025</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/appendix-4e-and-annual-report-to-shareholders-2025</guid>
<pubDate>Thu, 28 Aug 2025 03:54:56 GMT</pubDate>
<description>Appendix 4E and Annual Report to Shareholders 2025</description>
</item>
<item>
<title>CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-preparing-upgrade-adr-program-074300530</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-preparing-upgrade-adr-program-074300530</guid>
<pubDate>Fri, 22 Aug 2025 07:43:00 GMT</pubDate>
<description>Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025CLINUVEL’s primary listing on the ASX will remain unchanged as a result of the ADR uplistpreparation of Form 20-F for submission to U.S. SECNasdaq listing to enhance U.S. visibility, trading access and investor engagementapproximately 28% of CLINUVEL’s issued shares held by U.S.-based investorsno capital raising is proposed in connection with the</description>
</item>
<item>
<title>CLINUVEL preparing upgrade of ADR program, NASDAQ uplist</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-preparing-upgrade-of-adr-program-nasdaq-uplist</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-preparing-upgrade-of-adr-program-nasdaq-uplist</guid>
<pubDate>Fri, 22 Aug 2025 03:30:04 GMT</pubDate>
<description>CLINUVEL preparing upgrade of ADR program, NASDAQ uplist</description>
</item>
<item>
<title>Study confirms NB-UVB needed to activate repigmentation</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/study-confirms-nb-uvb-needed-to-activate-repigmentation</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/study-confirms-nb-uvb-needed-to-activate-repigmentation</guid>
<pubDate>Wed, 18 Jun 2025 03:56:06 GMT</pubDate>
<description>Study confirms NB-UVB needed to activate repigmentation</description>
</item>
<item>
<title>CLINUVEL management update</title>
<link>https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-management-update</link>
<guid isPermaLink="true">https://6ix.com/company/clinuvel-pharmaceuticals-ltd/news/clinuvel-management-update</guid>
<pubDate>Fri, 13 Jun 2025 03:56:06 GMT</pubDate>
<description>CLINUVEL management update</description>
</item>
</channel>
</rss>